CLAIMS

1. Use of Brain-derived nerve factor (BDNF) in the manufacture of a medicament for the treatment of rhodopsin-mediated retinitis pigmentosa in a subject, said BDNF to be administered as a protein.

2. The use as claimed in claim 1, wherein said rhodopsin-mediated retinitis pigmentosa is a rhodopsin-mediated autosomal dominant retinitis pigmentosa.

3. The use as claimed in claim 2, wherein said rhodopsin-mediated autosomal dominant retinitis pigmentosa is associated with a class I rhodopsin mutation.

4. The use as claimed in claim 3, wherein said class I rhodopsin mutation is selected from one of the following mutations:
L328P, T342M, Q344R, Q344P, Q344ter, V345L, V345M, A346P, P347A, P347R, P347Q, P347L, P347S, P347T, ter349Q, ter349E.

5. The use as claimed in claim 2, wherein said rhodopsin-mediated autosomal dominant retinitis pigmentosa is associated with a class II rhodopsin mutation.

6. The use as claimed in claim 5, wherein said class II rhodopsin mutation is selected from one of the following mutations:
N15S, T17M, V20G, P23A, P23H, P23L, Q28H, G51R, G51V, P53R, T58R, T58M, V87D, G89D, G106R, G106W, C110F, C110R, C110S, C110Y, E113K, L125R, W161R, A164E, A164V, C167R, C167W, P171Q, P171L, P171S, Y178N, Y178D, Y178C, E181K, G182S, G182V, C185R, C187G, C187Y, G188R, G188E, D190N, D190G, D190Y, H211R, H211P, C222R, P267R, P267L, S270R, K296N, K296E and K296M.

7. The use as claimed in claim 5, wherein said class II rhodopsin mutation is P23H.

8. The use as claimed in any one of claims 1 to 7, wherein said BDNF is to be administered to said subject by intravitreal injection.

9. The use as claimed in any one of claims 1 to 8, wherein said BDNF is human BDNF, preferably it is recombinant human BDNF.

10. The use as claimed in any one of claims 1 to 9, wherein said BDNF is to be administered to said subject by intravitreal injection in an amount/eye per each administration between 10 μg and 500 μg, preferably between 15 μg and 250 μg, more preferably between 18 μg and 50 μg, even more preferably of 20 μg.

11. Use of an ophthalmic composition comprising BDNF and at least one ophthalmically acceptable excipient, in the manufacture of a medicament for the treatment of rhodopsin-mediated retinitis pigmentosa in a subject, said BDNF to be administered as a protein.

12. The use as claimed in claim 11, wherein said BDNF is human BDNF, preferably it is recombinant human BDNF.

13. The use as claimed in claim 11 or 12, wherein said ophthalmic composition is a liquid composition.

14. The use as claimed in claim 13, wherein BDNF is contained in the composition at a concentration between 0.2 μg/μl and 10 μg/μl, preferably between 0.3 μg/μl and 5 μg/μl, more preferably between 0.35 μg/μl and 1 μg/μl, even more preferably of 0.4 μg/μl .

15. The use as claimed in any one of claims 11 to 14, wherein said ophthalmic composition is to be administered to said subject by intravitreal injection.